<DOC>
	<DOCNO>NCT02312687</DOCNO>
	<brief_summary>UX023-CL203 Phase 2b , open-label , long-term extension study . The study conduct adult assess safety pharmacodynamics KRN23 administer via subcutaneous injection monthly ( every 4 week ) total 68 week . The study enroll approximately 25 adult XLH participate Kyowa Hakko Kirin Pharma , Inc. 's ( KHK 's ) study KRN23-INT-001 KRN23-INT-002 . Subjects need discontinue oral phosphate vitamin D metabolite therapy prior enrollment throughout duration study .</brief_summary>
	<brief_title>Long-Term Extension Study KRN23 Adult Subjects With X-Linked Hypophosphatemia ( XLH )</brief_title>
	<detailed_description />
	<mesh_term>Familial Hypophosphatemic Rickets</mesh_term>
	<mesh_term>Hypophosphatemia</mesh_term>
	<criteria>1 . Have participate KHK 's KRN23INT001 KRN23INT002 study ( receive least 2 dos KRN23 ) 2 . Estimated glomerular filtration rate ( eGFR ) ≥60 mL/min Screening . 3 . Sexually active subject must willing use acceptable method contraception ( e.g. , double barrier method ) participate study 30 day receive last dose KRN23 . 1 . Subject experience safetyrelated event KRN23INT001 KRN23INT002 study , opinion investigator sponsor , precludes resume KRN23 treatment . 2 . Presence nephrocalcinosis renal ultrasound , opinion investigator sponsor , precludes resume KRN23 treatment . 3 . Pregnant breastfeed Screening plan become pregnant ( self partner ) time study . 4 . Participation investigational drug device trial within 30 day enrollment ( KRN23INT001 KRN23INT002 ) . 5 . Use pharmacologic vitamin D metabolite analog ( e.g. , calcitriol , doxercalciferol , paricalcitol ) , phosphate , aluminum hydroxide antacid ( e.g. , Maalox® Mylanta® ) within 21 day prior Screening study . 6 . Use medication suppress PTH ( e.g. , Sensipar® , cinacalcet , calcimimetics ) within 2 month prior Screening .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>XLH</keyword>
	<keyword>FGF23</keyword>
	<keyword>KRN23</keyword>
</DOC>